Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02502396 · ClinicalTrials.gov registry record
Rivaroxaban Utilization for Treatment and Prevention of Thromboembolism in Cancer Patients: Experience at a Comprehensive Cancer Center
A clinical trial, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- 265
- Enrollment target
NCT02502396: Completed study, sponsored by M.D. Anderson Cancer Center.
NCT02502396 is a clinical trial that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 265 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02502396 has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- 265 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the practice patterns of rivaroxaban usage invenous-thromboembolism (VTE) and non-valvular atrial fibrillation (NVAF) in cancer patients. The secondary objectives are to evaluate outcomes such as recurrent VTE, stroke and bleeding for cancer patients on rivaroxaban.
Interventions
- OTHER Retrospective Chart Review
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 265 participants |
| Start Date | 2015-09-28 |
| Est. Completion | 2022-03-15 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02502396
The ClinicalTrials.gov registry entry for NCT02502396 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 265 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Retrospective Chart Review is the first listed.
NCT02502396 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02502396 about?
NCT02502396 is a clinical study titled "Rivaroxaban Utilization for Treatment and Prevention of Thromboembolism in Cancer Patients: Experience at a Comprehensive Cancer Center". The primary objective of this study is to evaluate the practice patterns of rivaroxaban usage invenous-thromboembolism (VTE) and non-valvular atrial fibrillation (NVAF) in cancer patients. The secondary objectives are to evaluate outcomes such as recurrent VTE, stroke and bleeding for cancer patien...
What is the current status of trial NCT02502396?
This trial is currently completed. The enrollment target is 265 participants. The study started on 2015-09-28. Estimated completion is 2022-03-15.
What interventions are being tested in trial NCT02502396?
The interventions under investigation include: Retrospective Chart Review (OTHER).
Who is sponsoring clinical trial NCT02502396?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.